Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Stomach Neoplasms 2Lung Neoplasms 2Sarcoma 1Recurrence 1Myeloproliferative Disorders 1Multiple Myeloma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Advanced Non-Small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 2toripalimab 1sintilimab 1pemigatinib 1osimertinib 1durvalumab 1Vinorelbine 1Platinum Compounds 1Nivolumab 1Ipilimumab 1Drug Therapy 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non Small Cell Lung Cancer × pemigatinib × Thoracic × Clear all
NCT05004974 2024-03-12

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Phase 2 Unknown
20 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡